Key result
Cardiac resynchronization therapy may improve symptoms, exercise capacity, and left ventricular ejection fraction in hypertrophic cardiomyopathy patients with LBBB or end-stage disease.
Why the study?
Data regarding CRT in patients with HCM are scarce, requiring further assessment and contextualization of existing research.
Does cardiac resynchronization therapy improve symptoms and LV function in patients with hypertrophic cardiomyopathy and LBBB or prolonged QRS?
Does cardiac resynchronization therapy improve symptoms and LV function in patients with hypertrophic cardiomyopathy and LBBB or prolonged QRS?
Answers are grounded in this paper and cite their sources.
CRT may be a beneficial therapeutic option for specific subsets of HCM patients, such as those with myectomy-induced LBBB or end-stage dilated HCM with prolonged QRS, though more robust data is needed.
Hypertrophic cardiomyopathy (HCM) is an inherited primary myocardial disease characterized by asymmetrical/symmetrical left ventricle (LV) hypertrophy, with or without LV outflow tract (LVOT) dynamic obstruction, and poor prognosis. Cardiac resynchronization therapy (CRT) has emerged as a minimally invasive tool for patients with heart failure (HF) with decreased LV ejection fraction (LVEF) and prolonged QRS duration of over 120 ms with or without left bundle branch block (LBBB). Several HCM patients are at risk of developing LBBB because of disease progression or secondary to septal myomectomy, while others might develop HF with decreased LVEF, alleged end-stage/dilated HCM, especially those with thin myofilament mutations. Several studies have shown that patients with myectomy-induced LBBB might benefit from left bundle branch pacing or CRT to relieve symptoms, improve exercise capacity, and increase LVEF. Otherwise, patients with end-stage/dilated HCM and prolonged QRS interval could gain from CRT in terms of NYHA class improvement, LV systolic performance increase and, to some degree, LV reverse remodeling. Moreover, several electrical and imaging parameters might aid proper selection and stratification of HCM patients to benefit from CRT. Nonetheless, current available data are scarce and further studies are still required to accurately clarify the view. This review reassesses the importance of CRT in patients with HCM based on current research by contrasting and contextualizing data from various published studies.
No takes yet. Share an insight, caveat, or question.
Radu et al. (2023) conducted a review in Hypertrophic cardiomyopathy. Cardiac resynchronization therapy (CRT) was evaluated. Cardiac resynchronization therapy may improve symptoms, exercise capacity, and left ventricular ejection fraction in hypertrophic cardiomyopathy patients with LBBB or end-stage disease.
Synapse has enriched 10 related papers. Consider them for comparative context: